SG96534A1 - Anticancer gene therapy by modulation of the immune and/or inflammatory response - Google Patents

Anticancer gene therapy by modulation of the immune and/or inflammatory response

Info

Publication number
SG96534A1
SG96534A1 SG9608019A SG1996008019A SG96534A1 SG 96534 A1 SG96534 A1 SG 96534A1 SG 9608019 A SG9608019 A SG 9608019A SG 1996008019 A SG1996008019 A SG 1996008019A SG 96534 A1 SG96534 A1 SG 96534A1
Authority
SG
Singapore
Prior art keywords
agent
contg
immune
inflammatory response
genome
Prior art date
Application number
SG9608019A
Inventor
Bruce Acres
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9451366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG96534(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of SG96534A1 publication Critical patent/SG96534A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2033—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Use of a viral vector contg. in its genome a DNA fragment (I) contg. ≥ 1 gene encoding all or part of an agent (A) that modulates the immune and/or inflammatory response for the treatment of cancer in mammals is new. (A) can be a cell surface co-stimulatory molecule, a chemokine, a monoclonal antibody against a lymphocyte surface maker, a super antigen characteristic of an infectious organism (bacterium, virus or parasite), a polypeptide with adjuvant activity or esp. a cytokine. Also claimed is the use of a viral vector with positive tropism for cancer cells contg. in its genome a DNA fragment including ≥ 1 gene, encoding an agent able to destroy cancer cells, under control of appropriate expression elements, for selective delivery of the agent to cancerous tumours.
SG9608019A 1993-09-29 1994-09-28 Anticancer gene therapy by modulation of the immune and/or inflammatory response SG96534A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9311601A FR2710536B1 (en) 1993-09-29 1993-09-29 Anti-cancer use of a viral vector comprising a gene which modulates the immune and / or inflammatory response.

Publications (1)

Publication Number Publication Date
SG96534A1 true SG96534A1 (en) 2003-06-16

Family

ID=9451366

Family Applications (1)

Application Number Title Priority Date Filing Date
SG9608019A SG96534A1 (en) 1993-09-29 1994-09-28 Anticancer gene therapy by modulation of the immune and/or inflammatory response

Country Status (12)

Country Link
EP (2) EP0721510B1 (en)
JP (1) JP4094053B2 (en)
AT (2) ATE323774T1 (en)
AU (1) AU709336C (en)
DE (2) DE69434708T2 (en)
DK (2) DK0721510T3 (en)
ES (2) ES2260117T3 (en)
FR (1) FR2710536B1 (en)
HK (1) HK1042728B (en)
PT (2) PT721510E (en)
SG (1) SG96534A1 (en)
WO (1) WO1995009241A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
EP0759695B1 (en) * 1994-05-13 2006-11-08 Thomas Jefferson University A method of inducing an immune response using vaccinia virus recombinants, expressing the gm-csf gene
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
GB2324960A (en) * 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
BR9813930A (en) 1997-11-06 2006-12-19 Chiron Spa neisserial antigen
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
JP5102414B2 (en) 1998-05-01 2012-12-19 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Meningococcal antigens and compositions
CN100392082C (en) 1999-04-30 2008-06-04 启龙股份公司 Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
CN1416352B (en) 2000-01-17 2011-05-25 启龙股份公司 Outer membrane vesicle (OMV) vaccine comprising N. Meningitidis serogroup B outer membrane
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
EP1366167A2 (en) * 2001-01-26 2003-12-03 Transgene S.A. Biological organism for preparing pharmaceutical compositions for treating mammals
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
ES2386386T3 (en) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Immunization against Chlamydia trachomatis
EP1369491A1 (en) 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
JP4634710B2 (en) * 2002-07-31 2011-02-16 ゲネルクス コーポレーション Microorganisms and cells for tumor diagnosis and treatment
US7659241B2 (en) 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
AU2004289953B2 (en) 2003-06-18 2008-09-25 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
JP4792390B2 (en) 2004-03-29 2011-10-12 株式会社ガルファーマ Novel galectin-9 variant protein and use thereof
CA2621982C (en) * 2005-09-07 2017-11-28 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
RU2313349C2 (en) * 2006-01-16 2007-12-27 Михаил Аркадьевич Шурдов Method for treating oncological diseases
US20110206692A1 (en) 2006-06-09 2011-08-25 Novartis Ag Conformers of bacterial adhesins
US20090098529A1 (en) 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US8445270B2 (en) 2009-05-12 2013-05-21 Transgene S.A. Immortalized avian cell lines and use thereof
IN2012DN01577A (en) 2009-07-21 2015-06-05 Transgene Sa
TWI690322B (en) 2012-10-02 2020-04-11 法商傳斯堅公司 Virus-containing formulation and use thereof
JP6655618B2 (en) 2014-12-01 2020-02-26 トランジェーヌＴｒａｎｓｇｅｎｅ Stable liquid vaccinia virus formulation
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP2020519666A (en) 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Stable virus-containing composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020356A1 (en) * 1991-05-23 1992-11-26 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
WO1993017095A1 (en) * 1992-02-19 1993-09-02 The Scripps Research Institute In vitro activation of cytotoxic t cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2583429B1 (en) * 1985-06-18 1989-11-03 Transgene Sa INTERFERON U EXPRESSION VECTOR IN MAMMALIAN CELLS, PROCESS FOR IMPLEMENTING SAME AND PRODUCT OBTAINED, AND PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON U
FR2583770B1 (en) * 1985-06-21 1988-08-19 Transgene Sa EXPRESSION OF HUMAN IL-2 IN MAMMALIAN CELLS BY A RECOMBINANT POXVIRUS
CA2120503C (en) * 1991-10-04 2006-04-04 Glenn Dranoff The regulation of systemic immune responses utilizing cytokines and antigens
DE69230506T2 (en) * 1991-10-25 2000-06-21 Sidney Kimmel Cancer Center, San Diego LYMPHOKINE GENE THERAPY FOR CANCER IN COMBINATION WITH TUMORANTIGENS
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020356A1 (en) * 1991-05-23 1992-11-26 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
WO1993017095A1 (en) * 1992-02-19 1993-09-02 The Scripps Research Institute In vitro activation of cytotoxic t cells

Also Published As

Publication number Publication date
EP1156119B1 (en) 2006-04-19
FR2710536B1 (en) 1995-12-22
EP0721510A1 (en) 1996-07-17
DE69434708T2 (en) 2007-04-05
WO1995009241A2 (en) 1995-04-06
DE69433060D1 (en) 2003-09-25
AU709336C (en) 2002-06-13
HK1042728B (en) 2006-11-24
EP1156119B9 (en) 2006-08-30
AU709336B2 (en) 1999-08-26
JPH09502993A (en) 1997-03-25
ES2260117T3 (en) 2006-11-01
AU7815994A (en) 1995-04-18
WO1995009241A3 (en) 1995-06-22
HK1042728A1 (en) 2002-08-23
JP4094053B2 (en) 2008-06-04
DK0721510T3 (en) 2003-11-17
ES2204922T3 (en) 2004-05-01
PT1156119E (en) 2006-08-31
ATE247714T1 (en) 2003-09-15
EP1156119A3 (en) 2002-10-23
DE69433060T2 (en) 2004-06-03
DK1156119T3 (en) 2006-06-06
PT721510E (en) 2003-11-28
DE69434708D1 (en) 2006-05-24
FR2710536A1 (en) 1995-04-07
EP0721510B1 (en) 2003-08-20
EP1156119A2 (en) 2001-11-21
ATE323774T1 (en) 2006-05-15

Similar Documents

Publication Publication Date Title
AU709336C (en) Anticancer gene therapy by modulation of immune and/or inflammatory response
AU672195B2 (en) Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatment
Thompson et al. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
AU2006092A (en) Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
EP0668781A4 (en) Lymphokine gene therapy of cancer.
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
EP0816499A3 (en) Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
WO2018137643A1 (en) Application of oncolytic virus as immunostimulant for treating tumors and/or cancers
EP0174444A3 (en) Hepatitis surface antigen particle vaccine
CA2363269A1 (en) Dna vaccination for treatment of autoimmune disease
Wilczyńska et al. Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer.
Wang et al. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer
FR2785293B1 (en) NUCLEIC ACIDS AND POLYPEPTIDES SPECIFIC TO NEISSERIA PATHOGENIC STRAINS
EP0662150A4 (en) Maspin, a novel serpin with tumor suppressing activity.
Sikora First 5 years of gene therapy for cancer.
CN1283319C (en) Tumor vaccine constituting method by combining dendritic cell multiplication and chemotaxis factor and suicide gene
KR20040103941A (en) Microorganism for genetic therapeutic teatment of proliferative diseases
Lambin et al. Clostridium‐Mediated Transfer of Therapeutic Proteins to Solid Tumors
Connor et al. 298. Treatment of Subcutaneous Melanoma after Vaccination with Cells Expressing Xenoepitopes in the α (1, 3) Galactosiltransferase (αGT) Knockout Mouse Model
LLOYD CELL TO CELL TRANSFER OF INTERFERON-INDUCED ANTIPROLIFERATIVE ACTIVITY IN VITRO AND ANTIVIRAL ACTIVITY IN VIVO.
Knulst et al. Enhancement and suppression of DTH reactivity to Rauscher murine leukaemia virus induced tumour cell lines
CN1986792A (en) Exotic antigen marking method for pathogenic cell
Mukai et al. Efficacy of in vitro sensitized cells generated by in vivo priming with OK-432 for adoptive immunotherapy of the poorly immunogenic B 16-BL6 melanoma
ES8802250A1 (en) A method for obtaining DNA which codes for mutant tumour necrosis factor